Earnings call transcript: Absci Corp misses revenue forecast in Q1 2026

Absci reported Q1 2026 revenue of $215,000, well below the $1.43 million forecast, but EPS of -$0.19 slightly beat expectations of -$0.1943. Management said cash of $125.7 million should fund operations into the first half of 2028, while reiterating key ABS-201 milestones in 2H26 and early 2027 and introducing ABS-202. Shares were modestly volatile after the release, falling 0.84% after hours before rebounding 1.53% in premarket trading.

Analysis

The key read-through is that the market is no longer pricing ABSI as a conventional biotech with near-term revenue expectations; it is pricing it as a binary-duration story around two clinical catalysts. That means the revenue miss is largely noise, but it also means the stock is vulnerable to sharp de-rating if the upcoming PK/safety update does not validate the “few injections” thesis, because the current multiple is leaning hard on convenience premium rather than de-risked efficacy. The real near-term driver is not the 13-week hair count itself, but whether management can keep the 26-week endpoint as the only data point that matters; if investors start anchoring on the interim read as a proxy for ultimate efficacy, sentiment could break fast.

Second-order, the strategic shift away from oncology is actually incrementally bullish for the equity over the next 2-3 quarters because it reduces capital dispersion and makes the story legible to crossover healthcare investors: one platform, one core mechanism, two lead indications, plus optionality in I&I. The downside is that this narrows the company’s partnering surface area; by self-selecting into a DTC-like dermatology go-to-market, Absci is implicitly saying it needs clinical differentiation strong enough to fund commercialization later, which raises the bar for data quality. If ABS-201 merely matches existing therapies without clearly better durability or dosing, the market may start discounting the TAM rhetoric as aspirational rather than actionable.

Contrarian angle: the crowd is focused on whether the stock is “cheap” after a 400% run, but the more important issue is that implied expectations are now very high for a pre-commercial name with a beta above 2.0. The catalyst path is asymmetric over the next 6-9 months: a clean PK/safety read can extend momentum even before efficacy, while any immunogenicity, durability, or enrollment issue likely cuts the stock by a third despite ample cash runway. In other words, balance sheet risk is low; narrative risk is high. The best setup is to own optionality into the next data point, not to hold size through the full 26-week efficacy event unless the July/June PK package materially de-risks the mechanism.

Key Decisions for Investors

• Buy small ABSI common ahead of the next PK/safety update as a catalyst trade, but size for a 20-25% stop because the stock is trading on narrative momentum rather than hard commercialization cash flows.
• Structure a call spread in ABSI into the interim 13-week readout, keeping delta positive but capping premium at risk; the better risk/reward is on a pre-POC continuation move than on chasing after the efficacy print.
• If long healthcare growth baskets, pair long ABSI / short a cash-burning non-catalyst biotech ETF basket over the next 1-2 months to isolate idiosyncratic catalyst exposure from broader biotech risk-off.
• Use any post-PK relief rally to reduce size into the 26-week readout unless efficacy is clearly above the “comparable with convenient dosing” threshold; below that bar, upside becomes TAM-story dependent and multiple compression risk rises.
• For more defensive exposure, prefer waiting for the June/next-month PK data before initiating a full position; if dosing interval and receptor occupancy are validated, that is the higher-conviction entry versus buying after a hot post-earnings squeeze.